[{"id":"a1087211-347a-4460-946c-85e3dc0c74dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04806659","created_at":"2021-03-19T15:59:03.686Z","updated_at":"2024-07-02T16:36:33.044Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia","source_id_and_acronym":"NCT04806659","lead_sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SH1573"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-03-19"}]